Question 1

What is Onco-Innovations?

Accepted Answer

Onco-Innovations is a Entity.

Question 2

How often does Onco-Innovations appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was Onco-Innovations first tracked by Ergen?

Accepted Answer

First tracked on Apr 17, 2026.

Question 4

When was Onco-Innovations last mentioned in news?

Accepted Answer

Last active on Jun 25, 2026.

Question 5

What is Onco-Innovations's current news sentiment?

Accepted Answer

Aggregate sentiment score: 50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Onco-Innovations in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Onco-Innovations?

Accepted Answer

Onco-Innovations Appoints New Leadership (Apr 17, 2026, 6 articles).

Question 8

How did the "Onco-Innovations Appoints New Leadership" event impact Onco-Innovations?

Accepted Answer

Onco-Innovations strengthened its clinical and development capabilities by appointing Dr. Islam Mohamed as CMO and Stephen M. Novak as Chief of R&D, aiming to advance its lead product candidate ONC010 into clinical trials.

Question 9

How did the "Onco-Innovations Limited featured in BioMedWire" event impact Onco-Innovations?

Accepted Answer

Onco-Innovations is the subject of the editorial, highlighting its leading position in developing next-generation DNA repair inhibitors for cancer treatment. This event increases its visibility and potential investor interest.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.